Healthcare
Live Price
Offline$3.27
-17.22% today
1Y Change
+19.22%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Raia Drogasil S.A. (RADLY) is a Healthcare stock with a market cap of $38.34B and listed on OTC. The stock last traded around $3.27 and up 19.2% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +11.6%, EPS growth of +5.5%, a dividend yield of 1.8%. What stands out right now is revenue +11.6%, EPS +5.5%, free cash flow +60.2% with operating margin 5.9% and ROIC 14.0%. The dividend is present but secondary, with a yield around 1.8%. Valuation is more restrained than many high-expectation growth names at P/E 29.6 and price/sales 0.9. Stock Foundry combines RADLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RADLY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RADLY Max Drawdown
-35.28%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RADLY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$24.1B
-17.0% YoY
FY Net Income
$751.9M
-24.5% YoY
Free Cash Flow
$694.9M
+40.8% YoY
Revenue Growth
+11.6%
EPS Growth
+5.5%
Gross Margin
27.0%
Net Margin
2.9%
Income statement
BRL
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 43.4B | 38.9B | 34.0B | 29.1B | 24.1B |
| Gross Profit | 10.7B | 11.5B | 10.2B | 8.8B | 7.2B |
| Operating Income | 2.6B | 2.4B | 2.1B | 1.5B | 1.2B |
| EBITDA | 4.6B | 3.1B | 2.8B | 2.5B | 2.6B |
| Net Income | 1.3B | 1.2B | 1.1B | 996M | 752M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
BRL
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 509M | 528M | 412M | 434M | 356M |
| Total Assets | 25.5B | 22.1B | 20.1B | 17.2B | 14.8B |
| Total Liabilities | 18.1B | 15.7B | 14.1B | 11.8B | 10.1B |
| Shareholder Equity | 7.3B | 6.4B | 6.0B | 5.3B | 4.7B |
| Total Debt | 8.8B | 7.7B | 7.1B | 6.1B | 5.2B |
| Net Debt | 8.3B | 7.2B | 6.7B | 5.6B | 4.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.6B
-7.8% YoY
Capital Expenditures
856M
+28.0% YoY
Free Cash Flow
695M
+40.8% YoY
Key ratios
Gross Margin
27.0%
Operating Margin
5.9%
Net Margin
2.9%
ROE
18.9%
Debt / Equity
1.21x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.